Truist Securities Reiterates Buy on Iovance Biotherapeutics, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Asthika Goonewardene has reiterated a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a price target of $17.
December 27, 2023 | 1:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities analyst Asthika Goonewardene has reiterated a Buy rating on Iovance Biotherapeutics with a maintained price target of $17.
The reiteration of a Buy rating by a prominent analyst can positively influence investor sentiment and potentially lead to a short-term increase in the stock price. The maintained price target of $17 suggests a level of confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100